PharmaLectures.com

Courses › Regulatory affairs by region › United States: 505(b)(2) and NDA basics for the generic that is not quite a generic

United States: 505(b)(2) and NDA basics for the generic that is not quite a generic

Keep Refuse-to-File letters off the launch timeline of your 505(b)(2) product.

  • 8 audio modulesthree lengths each
  • 1 h 20 min to 6 h 40 minbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • RA, QA, BDwho it is written for

Why this training matters

Your team files a 505(b)(2) application. Inside the 60-day filing review, a Refuse-to-File letter arrives citing section 314.101 of Title 21 of the Code of Federal Regulations, because the bridge to the listed drug is missing. The launch date moves while you rebuild the package.

What changes after this course

Your team settles the pathway, lists the bridging data and checks the dossier before anyone writes a page. You hold a certificate for each learner and a training record for each person, ready for your auditor.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory affairs team settles the pathway question in one meeting. They check the Orange Book, compare your product with the reference listed drug, and choose between 505(b)(1), 505(b)(2) and 505(j) on paper, not by argument. Legal gets a one-page rationale instead of a question, and the patent certification under 21 CFR 314.50(i) is on the plan from day one.

The nonclinical and clinical plan stops growing. Before a single study is booked, the team lists what the listed drug's record already covers and what the Food and Drug Administration will still ask for. Toxicology studies nobody needed stay off the schedule, and the one bridging study that is needed stays on it.

Quality assurance reads Module 3 the way a reviewer will. Specifications, stability data and the manufacturing description are checked against each other, and Form 356h is checked against all of them. Gaps surface in your own review, not in an information request or a Refuse-to-File letter under 21 CFR 314.101.

Business development gets a sharper eye for 505(b)(2) deals. In due diligence, the team can see whether the target's bridge holds, whether the Pre-New Drug Application meeting minutes say what the seller claims, and which post-marketing commitments and annual report duties come with the product.

Who needs this training

  • Regulatory Affairs Specialist

    The day a product team asks which application type fits, you answer from the Orange Book and the Federal Food, Drug, and Cosmetic Act, then build the dossier and the briefing questions around that choice.

  • Quality Assurance Manager

    Before Module 3 ships, you check specifications, stability data and site details against each other and catch the mismatch that would otherwise come back as an information request.

  • Business Development Manager

    When a 505(b)(2) asset lands on your desk, you read the bridge, the meeting minutes and the commitments list, and you know which gaps change what the asset is worth to you.

Roles: Business development and export sales, Regulatory affairs, Quality assurance and Qualified Person

Businesses: every kind of pharma company

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: United States

Courses are in English. Other languages on request.

After this course your people can

  1. Decide between 505(b)(1), 505(b)(2) and 505(j) for a given product and write the one-page rationale.
  2. List which nonclinical findings can come from the listed drug and which need a new study.
  3. Select the bioavailability or bioequivalence study that bridges your product to the reference listed drug under 21 CFR Part 320.
  4. Check a Module 3 draft for mismatches between specifications, stability data and the manufacturing description.
  5. Place each document in the correct one of the five Common Technical Document modules, including Form 356h in Module 1.
  6. Draft the questions for a Pre-New Drug Application meeting so that each one can be answered directly.
  7. Build a calendar of post-marketing commitments and annual report items under 21 CFR 314.81 with a named owner for each.

What the company gets

  • Your team files 505(b)(2) dossiers where the bridge to the listed drug is already visible, so the filing review has less reason to stop.
  • Studies nobody asked for come off the plan, and the studies the Food and Drug Administration does expect are booked early.
  • Quality assurance hands over a Module 3 whose specifications, stability data and site details agree with each other.
  • When a partner or auditor asks who owns each post-marketing commitment, your team answers from a named list, and you hold a training record for each person.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 8 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h 20 min10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard3 h 20 min25 min a module, for regulatory, quality and business-development staff
Expanded6 h 40 min50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Business development and export salesBriefing1 h 20 min
Regulatory affairsStandard3 h 20 min
Quality assurance and Qualified PersonStandard3 h 20 min

Course outline: 8 modules

8 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Select the right United States approval pathway for each product you develop

    • Why the reference listed drug in the Orange Book decides which pathway you can use.
    • How to tell in one meeting whether your product belongs under 505(b)(1), 505(b)(2) or 505(j).
    • What to do when two pathways both fit and your launch date has to pick one.
  2. 2Use 505(b)(2) to file a hybrid product on existing safety findings

    • The changes in strength, dosage form or route that make a product eligible for 505(b)(2).
    • How to rely on the Food and Drug Administration's earlier findings without owning the data.
    • Why the patent certification in 21 CFR 314.50(i) can move your launch date more than the science.
  3. 3Bridge nonclinical data from the listed drug to your submission

    • When you must run new toxicology studies and when the listed drug's record is enough.
    • How to write the nonclinical bridge so a reviewer sees the link in one read.
    • The literature gaps that a pharmacology and toxicology reviewer finds first.
  4. 4Pin down the clinical studies your 505(b)(2) application needs

    • Which bioavailability and bioequivalence studies under 21 CFR Part 320 your change calls for.
    • How a missing clinical bridge becomes a Refuse-to-File letter under 21 CFR 314.101.
    • What to do when the change is too big for a bioequivalence study alone to carry it.
  5. 5Write the Chemistry, Manufacturing, and Controls sections reviewers accept

    • The drug product details in Module 3 that stop a quality reviewer from sending an information request.
    • How to show your manufacturing site is ready for the pre-approval inspection.
    • Why stability data and specifications must agree before anyone signs the Module 3 summary.
  6. 6Build your dossier across the five Common Technical Document modules

    • How to place each document across Module 1 to Module 5 so the filing reviewer finds it.
    • How to complete Form 356h so it matches every module behind it.
    • When to write the Module 2 summaries so they match the data in Modules 3, 4 and 5.
  7. 7Run a Pre-New Drug Application meeting that ends with usable answers

    • How to write the briefing package questions so each one earns a direct answer.
    • What to do when the minutes arrive and do not say what the meeting said.
    • The questions to put to the review division about your bridge before the dossier is final.
  8. 8Track post-marketing commitments and file annual reports on time

    • How to separate post-marketing requirements from commitments so each has an owner and a date.
    • Which annual report items under 21 CFR 314.81(b)(2) your team gathers during the year.
    • Why a missed report date lands on the company, and what to do when you are already late.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

8 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h 20 min in the briefing length and 6 h 40 min in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for RA, QA, BD. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 72 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team